Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Pfizer Inc.

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
FDA and EMA Accept Regulatory Submission for Pfizer’s Ritlecitinib for Individuals 12 Years and Older with Alopecia Areata
From Pfizer Inc.
Via Business Wire
Tickers PFE
FDA Grants Breakthrough Therapy Designation to Pfizer’s Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Climate Action
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer Announces Positive Top-Line Data from Phase 3 Trial of Older Adults for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
From Pfizer Inc.
Via Business Wire
Tickers PFE VALN
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
From Pfizer Inc.
Via Business Wire
Tickers PFE
PFIZER REPORTS SECOND-QUARTER 2022 RESULTS
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID™
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
From Pfizer Inc.
Via Business Wire
Tickers PFE ROIV
Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Declares Third-Quarter 2022 Dividend
From Pfizer Inc.
Via Business Wire
Tickers PFE
Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15
From Pfizer Inc.
Via Business Wire
Tickers PFE VALN
Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDA
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Completes Acquisition of ReViral
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S.
From Pfizer Inc.
Via Business Wire
Tickers PFE
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.